A drug originally used to boost the immune system is showing promise as a potential new treatment for lupus, joint Monash University and Peking University research published today shows. Lupus is an autoimmune disease, where the immune system attacks the body’s own organs and tissues.
An international team of scientists from Australia and China have, for the first time, shown in a study published in Nature Medicine, that a natural immune system protein called IL-2 can help restore balance to the overactive immune system of lupus patients. The drug could soon be rolled out for clinical trials in lupus treatment.
Monash Biomedicine Discovery Institute researcher, Dr Di Yu and Professor Zhanguo Li from Peking University People’s Hospital in China co-led the study.
Dr Yu said he hoped the drug could be approved as a lupus treatment within a handful of years.
“This drug, which can help the immune system fight against cancer, was approved in the 1990s but is not commonly used now. We’re now using this drug for a different purpose, based on our new knowledge of the immune system,” Dr Yu said.
“The amount we tested for treating lupus is much less than the dose used in treating cancers. We observed the treatment was safe and showed promising results, so there’s reason to believe formal trials could begin almost immediately,” he said.
Dr Yu said lupus could be a serious disease, and that it hadn’t been able to be treated in a very satisfactory way in the past.
IL-2 is a protein that regulates the activity of white blood cells, which are an important part of the immune system that protect the body against infections. In cancer therapy, patients are given large doses of IL-2 to stimulate their immune system but, paradoxically, the low dose IL-2 given to lupus sufferers in this study actually supressed the overactive part of their immune system that attacks their body. The research also showed the “self-checking” part of the immune system that prevents an overactive immune response, called regulatory T cells, increased after IL-2 treatment.
Professor Eric Morand, fellow Monash University researcher on the study and founder of the Asia Pacific Lupus Collaboration, said that in this study, IL-2 was given to people whose lupus wasn’t responding well to standard treatments.
“The real promise of this treatment is that it calms the hyperactive immune system through multiple mechanisms, which is very important as this new therapy may be effective for many patients,” Professor Morand said.
”As the drug has been on the market for some time for other diseases, it can be rapidly put into formal trials for lupus treatment right away.”
Learn more: Promising new treatment for lupus on the horizon
The Latest on: Lupus
via Google News
The Latest on: Lupus
- Flipping the script on novel cancer therapy leads to insights into lupuson December 12, 2019 at 12:10 am
Now Yale scientists have essentially flipped this script and found that when impaired a molecularly similar regulator can cause the damaging immune system attacks on skin and organs that are the ...
- How to Test for Lupuson December 11, 2019 at 10:06 am
Diagnosing lupus is somewhat like reaching a verdict in a murder trial without an eyewitness, says Dr. S. Sam Lim, a professor of medicine and epidemiology and clinical director of rheumatology at ...
- Polyautoimmunity Common in Lupuson December 10, 2019 at 12:04 pm
A substantial number of patients with systemic lupus erythematosus (SLE) had features of other autoimmune conditions, but treatment with the antimalarial hydroxychloroquine appeared to be protective ...
- Equillium Granted U.S. FDA Fast Track Designation for Itolizumab for the Treatment of Lupus Nephritison December 9, 2019 at 4:27 pm
Equillium initiated the EQUALISE Phase 1b study of itolizumab in patients with lupus and lupus nephritis in September 2019. The FDA’s Fast Track program is designed to facilitate the development of ...
- Bach2 deficiency leads autoreactive B cells to produce IgG autoantibodies and induce lupus through a T cell-dependent extrafollicular pathwayon December 9, 2019 at 1:22 am
2a, b). The Bach2-deficient mice also had elevated histopathologic indexes of lupus nephritis, as judged by their hypercellularity score and the percentage of proliferating glomeruli (Fig. 2c, d).
- Lupus Diet and Nutritionon December 6, 2019 at 12:16 pm
Lupus is an autoimmune condition that causes constant fatigue, skin rashes, and joint pain and swelling. The most common form of lupus, called systemic lupus erythematosus, may involve inflammation in ...
- Aurinia's Successful Study In Lupus Nephritis Changes The Scope Of Treatment Options For Patientson December 6, 2019 at 9:59 am
Aurinia Pharmaceuticals achieved primary endpoint in phase 3 AURORA study using voclosporin to treat patients with lupus nephritis. Voclosporin with background CellCept and low-dose corticosteroids ...
- AURORA study: Voclosporin safe, effective for lupus nephritison December 6, 2019 at 6:44 am
Phase 3 results from the AURORA study demonstrated combining voclosporin with mycophenolate and low-dose corticosteroids was superior to standard care for treating patients with lupus nephritis. The ...
- Aurinia soars as phase 3 lupus study hits primary endpointon December 5, 2019 at 3:30 am
A phase 3 trial of Aurinia Pharmaceuticals’ voclosporin in lupus nephritis has hit its primary endpoint, causing the company's share price to double. The data tee Aurinia up to file for FDA approval ...
- Monumental Treatment Breakthrough for Lupus Kidney Diseaseon December 4, 2019 at 4:07 pm
Trial of Voclosporin Meets All Primary and Secondary Endpoints with Clean Safety Profile WASHINGTON, Dec. 4, 2019 /PRNewswire/ -- Today, Aurinia Pharmaceuticals Inc. announced very positive top-line ...
via Bing News